Neurol. praxi. 2019;20(1):67-72 | DOI: 10.36290/neu.2019.093

Brivaracetam (Briviact®)

prof. MUDr. Milan Brázdil, Ph.D.
Centrum pro epilepsie Brno, 1. neurologická klinika FN u sv. Anny a LF MU v Brně

New AED Briviact® described below is actually registered in EU and indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. The efficacy and safety profile of brivaracetam was established in 3 randomized, clinical trials. The most frequently reported adverse reactions with brivaracetam were somnolence and dizziness. Its main mode of action is a high and selective affinity for synaptic vesicle protein 2A. The binding affinity of brivaracetam for SV2A is twenty times higher compared with levetiracetam. The biggest benefit is that Briviact® delivers a therapeutic dose to patients from first day of use without titration.

Keywords: epilepsy, Brivaracetam, SV2A

Published: March 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brázdil M. Brivaracetam (Briviact®). Neurol. praxi. 2019;20(1):67-72. doi: 10.36290/neu.2019.093.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014; 55: 57-66. Go to original source... Go to PubMed...
    2. Briviact(R), SPC. Souhrn údajů o přípravku. 07/2018. Dostupné na http://www.ema.europa.eu
    3. French JA, Costantini C, Brodsky A, von Rosenstiel P; N01193 Study Group. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010; 75: 519-525. Go to original source... Go to PubMed...
    4. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convul - sant properties. Eur J Pharmacol. 2011; 664: 36-44. Go to original source... Go to PubMed...
    5. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001; 52(4): 349-355. Go to original source... Go to PubMed...
    6. Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720. Go to original source... Go to PubMed...
    7. Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P. A randomized, double-blind, placebo controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015; 56: 1890-1898. Go to original source... Go to PubMed...
    8. Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014; 55: 38-46. Go to original source... Go to PubMed...
    9. Löscher W, Luna-Tortós C, Römermann K, Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des. 2011; 17(26): 2808-2828. Go to original source... Go to PubMed...
    10. Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008; 55(8): 1364-1375. Go to original source... Go to PubMed...
    11. Margineanu DG, Klitgaard H. Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. Seizure. 2009; 18: 453-456. Go to original source... Go to PubMed...
    12. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. British Journal of Pharmacology 2008; 154(8): 1662-1671. Go to original source... Go to PubMed...
    13. Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2016; 57(2): 201-209. Go to original source... Go to PubMed...
    14. Quarato PP, Whitesides J, D'Souza J, Johnson ME, Schiemann J. Efficacy and safety of adjunctive brivaracetam for partial-onset (focal) seizures: Pooled results from three fixed-dose, randomized, double-blind, placebo-controlled Phase III studies. Poster presented at the 31st International Epilepsy Congress, Istambul, Turkey, September 2015. Go to original source...
    15. Rogawski MA. Brivaracetam: a rational drug discovery success story. British Journal of Pharmacology. 2008; 154(8): 1555-1557. Go to original source... Go to PubMed...
    16. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-con - trolled trial. Epilepsia 2014; 55: 47-56. Go to original source... Go to PubMed...
    17. Stockis A, Rolan P. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol. 2013; 53: 1313-1321. Go to original source... Go to PubMed...
    18. Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia 2014; 55: 27-31. Go to original source... Go to PubMed...
    19. Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015; 113: 19-27. Go to original source... Go to PubMed...
    20. Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016; 57(7): 1139-1151. Go to original source... Go to PubMed...
    21. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013; 54(1): 89-97. Go to original source... Go to PubMed...
    22. Wasterlain CG, Suchomelova L, Matagne A. Short-term and long-term effects of brivaracetam in an animal model of status epilepticus. Epilepsia 2009; 50(Suppl. 10): 13.
    23. Wood MD, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 2017; 58(2): 255-262. Go to original source... Go to PubMed...
    24. Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res. 2010. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.